Dr Reddy’s scrip surged 9.75% to settle at Rs2,217.35 on BSE.On NSE, it climbed 9.73% to close at Rs2,217.55. Photo: MintNew Delhi: Shares of Dr Reddy’s Laboratories on Friday soared nearly 10% after Nasdaq-listed Vivus Inc entered into a settlement agreement with the company to resolve a long-pending patent litigation related to weight management capsule Qsymia. The stock surged 9.75% to settle at Rs2,217.35 on BSE. The settlement permits the Hyderabad-based drugmaker to begin selling a generic version of Qsymia from June 2025, or earlier under certain circumstances. In the event of an early launch, Vivus will receive a royalty on sales of the generic version of the drug.

Source: Mint September 01, 2017 10:09 UTC